Keizman, D
Fosboel, M O
Reichegger, H
Peer, A
Rosenbaum, E
Desax, M-C
Neiman, V
Petersen, P M
Mueller, J
Cathomas, R
Gottfried, M
Dresler, H
Sarid, D
Mermershtain, W
Rouvinov, K
Mortensen, J
Gillessen, S
Daugaard, G
Omlin, A
Article History
Received: 21 September 2016
Revised: 12 December 2016
Accepted: 20 December 2016
First Online: 28 February 2017
Competing interests
: DK is a member of the advisory boards and speaker for Astellas, Bayer, BMS, Janssen, MSD, Novartis, Pfizer, Sanofi, Teva. AO is a member of the advisory boards (compensated, institutional) for Bayer, Astellas, Janssen, Sanofi, Pfizer. Travel support was provided by Bayer, Astellas, Janssen, Sanofi. Research support was provided by Janssen, Teva. J Mortensen is a member of the advisory board (without honorarium) in Bayer. SG is an advisor for Active Biotech, Astellas, Bayer, Bristol-Myers Squibb, Curevac, Dendreon, Ferring, Janssen Cilag, Janssen Diagnostics MaxiVAX, Millennium, Novartis, Orion Pharma, Pfizer, Sanofi Aventis, ProteoMediX, ESSA Pharmaceuticals Corp, Nectar. Speakers Bureau comprises Amgen, Astellas, Bayer, Janssen Cilag, Novartis, Sanofi Aventis. Patent application for a method for biomarker WO 2009138392 A1 is pending. RC is a member of the advisory board for Astellas, Bayer, Janssen, Sanofi. GD has an advisory board role in Bayer, Janssen Cilag, Pfizer, Sanofi Aventis. PMP has an advisory board role in Bayer. The remaining authors declare no conflict of interest.